Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform

Area of Science:

• Genetics
• Molecular Diagnostics
• Cardiovascular Disease Research

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol.
• Accurate genetic diagnosis is crucial for timely intervention and management of FH.
• Existing genetic testing methods can be costly and time-consuming.

Purpose of the Study:

• To validate the Lipochip genetic diagnostic platform for FH identification in Spain.
• To assess the platform's effectiveness, sensitivity, specificity, and cost-efficiency.
• To compare Lipochip performance against established genetic testing techniques.

Main Methods:

• Utilized the Lipochip platform, including DNA microarray and gene sequencing, for analyzing DNA samples from clinically diagnosed FH patients.
• Confirmed Lipochip results through independent DNA sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis.
• Evaluated diagnostic accuracy metrics (sensitivity, specificity) and turnaround time.

Main Results:

• Lipochip detected mutations in 66% of 808 tested FH patients, with 78% identified via microarray.
• Achieved high diagnostic accuracy: 99.8% sensitivity and 99.5% specificity.
• Provided results within 22 days at an average cost of $350 per case, significantly lower than alternatives.

Conclusions:

• The Lipochip platform is a reliable, rapid, and economical option for genetic testing in clinically diagnosed FH patients.
• This validated platform can improve the efficiency of FH diagnosis in Spain.
• Lipochip facilitates earlier identification and management of individuals with FH.